Reality Check on Attention Deficit Hyperactivity Disorder (ADHD)
Market access for attention deficit hyperactivity disorder (ADHD) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, more than 45% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In April 2019, the FDA permitted marketing of the first medical device, called the Monarch external Trigeminal Nerve Stimulation System, to treat ADHD. It is indicated for patients ages 7 to 12 years old who are not currently taking prescription ADHD medication
- Key Findings: The utilization management with these drugs centers around quantity limit and step therapy. If a prior authorization (PA) exists, it is usually to confirm diagnosis. In some cases, PAs only apply to specific age groups
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.